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PBMCsGrifﬁthsin (GRFT) is possibly the most potent anti-HIV peptide found in natural sources. Due to its potent and
broad-spectrum antiviral activity and unique safety proﬁle it has great potential as topical microbicide
component. Here, we evaluated various combinations of GRFT against HIV-1 clade B and clade C isolates in
primary peripheral blood mononuclear cells (PBMCs) and in CD4+ MT-4 cells. In all combinations tested,
GRFT showed synergistic activity proﬁle with tenofovir, maraviroc and enfuvirtide based on the median effect
principle with combination indices (CI) varying between 0.34 and 0.79 at the calculated EC95 level.
Furthermore, the different glycosylation patterns on the viral envelope of clade B and clade C gp120 had no
observable effect on the synergistic interactions.
Overall, we can conclude that the evaluated two-drug combination increases their antiviral potency and
supports further clinical investigations in pre-exposure prophylaxis for GRFT combinations in the context of
HIV-1 clade C infection.. Férir),
e.schols@rega.kuleuven.be
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
The broad genetic diversity of human immunodeﬁciency viruses
makes it very difﬁcult to generate an effective vaccine (McElrath and
Haynes, 2010). While HIV-1 clade C dominates the HIV-1 epidemic
worldwide with N50% of the total viral infections, predominately in
Southern Africa, India and other parts of Asia, HIV-1 subtype B is
mainly found in (Western-) Europe and in the Americas, accounting
around 10% of the total infections (Buonaguro et al., 2007). In areas
where they have been recently introduced, like Brazil, Clade C viruses
become rapidly established, and have started to replace the previously
dominant Clade B epidemic (de Oliveira et al., 2010). The standard
combination antiretroviral therapy does not cure HIV, making
prevention of novel infections of extreme importance. A high number
of the new HIV infections occur through heterosexual intercourse.
Therefore, self-administered topical microbicides (e.g. vaginal gel or
intravaginal ring devices) could be very helpful tools to reduce the
infection rates. In the last decade, many microbicidal clinical trials
failed due to safety problems or lack of efﬁcacy (Lacey et al., 2010;
McCormack et al., 2010; Van Damme et al., 2008). However, recently a1% tenofovir gel product showed partial efﬁcacy in prevention of HIV-
1 transmission (Abdool Karim et al., 2010). As for systemic HIV
treatment, the most effective HIV prophylaxis strategy will involve
combinations of various antiretroviral drugs. Viral entry is considered
an important target in combating HIV/AIDS infections and thus entry
inhibitors are proposed as candidates for microbicidal applications.
The gp41 fusion peptide inhibitor enfuvirtide (Fuzeon) was the ﬁrst
clinically approved entry inhibitor and has clearly proven its
effectiveness (Kilby et al., 1998; Kilby et al., 2002). The only HIV co-
receptor inhibitor, the CCR5 antagonist maraviroc (Selzentry), was
approved for the treatment of HIV infections, in combination with
other antiretroviral drugs (MacArthur and Novak, 2008).
At present, grifﬁthsin (GRFT) is possibly the most potent and
broad-spectrum HIV entry inhibitor as it inhibits viral replication at
pM levels by speciﬁcally targeting multiple mannose-rich residues
present on the viral envelope protein gp120 (Emau et al., 2007; Mori
et al., 2005). GRFT has a molecular weight of 12.7 kDa and was
originally isolated from the red alga Grifﬁthsia sp. (Mori et al., 2005). It
contains 121 amino acids and has a unique dimeric structure
(Ziółkowska et al., 2006). Production of recombinant forms of GRFT
in E. coli and in theNicotiana benthamiana plant did not alter its potent
anti-HIV activity (IC50: 0.043–0.63 nM) nor its safety proﬁle com-
pared with native isolated GRFT (CC50: N1000 nM) (Mori et al., 2005;
O'Keefe et al., 2009). Besides inhibiting HIV-1 subtype B strains, GRFT
was also able to potently inhibit HIV-1 clade A and clade C viruses
Table 1
EC50 values of GRFT (nM), tenofovir (μM), maraviroc (nM) and enfuvirtide (nM) alone and in combination at equipotent (1:1) ratio against R5 HIV-1 in PBMCs.
EC50 individual druga EC50 combinationb
GRFT Inhibitor GRFT Inhibitor
Clade B/BaL Tenofovir 0.16±0.02 1.3±0.9 0.05±0.02⁎ 0.64±0.19
Maraviroc 0.17±0.02 6.6±1.9 0.05±0.01⁎ 2.3±0.6
Enfuvirtide 0.21±0.01 41.0±7.3 0.06±0.01⁎ 5.6±1.6⁎
Clade C/DJ259 Tenofovir 0.11±0.01 0.95±0.19 0.07±0.01⁎ 0.84±0.03
Maraviroc 0.34±0.30 1.6±0.9 0.03±0.01 0.48±0.14
Clade C/ZAM18 Tenofovir 0.61±0.01 0.53±0.37 0.12±0.08⁎ 0.27±0.11
Maraviroc 1.8±0.6 4.4±1.7 0.57±0.30 3.4±1.4
Clade C/ETH2220 Tenofovir 0.59±0.06 0.72±0.11 0.05±0.01⁎ 0.59±0.03
Maraviroc 0.69±0.19 3.1±1.5 0.13±0.02⁎ 2.1±0.4
a 50% effective concentration for HIV-1 infection in PBMCs after single drug treatment. Mean EC50s±SEM of 2–4 donors are shown.
b 50% effective concentration after two-drug combination at equipotent ratio (1:1).
⁎ pb0.05 (unpaired T-test), compared to single drug treatment.
A
B
C
Fig. 1. The activity proﬁle against R5 HIV-1 BaL replication (% virus production
measured by p24 HIV-1 core Ag ELISA 10 days post-infection) in PBMCs of GRFT alone
or combined with tenofovir (A), or with maraviroc (B) or with enfuvirtide (C). A
representative donor is shown from 4 different PBMCs donor experiments.
254 G. Férir et al. / Virology 417 (2011) 253–258isolated from blood and cervico-vaginal samples (Alexandre et al.,
2010; O'Keefe et al., 2009). Glycosylation patterns between different
HIV-1 clades vary (Zhang et al., 2004) and thus play an important role
in the antiviral activity of carbohydrate-binding agents (CBAs).
Molecular studies with GRFT have shown that introduction of the
glycosylation sites N234 and N295 in HIV-1 clade C virus increased its
potency (Alexandre et al., 2010).
Here, we describe that GRFT acts synergistically with tenofovir,
maraviroc and enfuvirtide in PBMCs against R5 HIV-1 clade B BaL. We
observed synergistic effects with the combination of GRFT/tenofovir
and GRFT/maraviroc on 3 different R5 clade C HIV-1 clinical isolates
(DJ259, ZAM18 and ETH2220) with different glycosylation patterns.
Additionally, synergistic interactions were also observed in MT-4 cells
against X4 HIV-1 NL4.3 with GRFT/tenofovir, GRFT/AMD3100 and
GRFT/enfuvirtide. These data show that combination of GRFT with
tenofovir, maraviroc or enfuvirtide increases antiviral potency and
support further clinical research on these combinations as potential
microbicide also in the context of HIV-1 clade C infections.
Results
GRFT is synergistic with tenofovir, maraviroc and enfuvirtide against
clade B HIV-1 R5 strain BaL in PBMCs
First, we determined the 50% effective concentrations (EC50s) of
GRFT, tenofovir, maraviroc and enfuvirtide alone, followed by the
two-drug combinations GRFT/tenofovir, GRFT/maraviroc and GRFT/
enfuvirtide against HIV-1 R5 clade B BaL replication. The EC50s of each
inhibitor alone and in combination are shown in Table 1. Overall, GRFT
inhibits HIV-1 BaL with an average EC50 of 0.18 nM and signiﬁcant
reductions (pb0.05) in GRFT concentrations were noted after
combination with tenofovir (p=0.048), maraviroc (p=0.0094) and
enfuvirtide (pb0.0001). A statistical signiﬁcant difference was also
calculated for enfuvirtide in combination with GRFT (p=0.0032)
using the unpaired T-test when compared to single drug treatment
(Table 1). As shown in Fig. 1, combination of GRFT with each inhibitor
tested, resulted in a more efﬁcient inhibitory proﬁle against HIV-1
replication as measured by p24 HIV-1 core Ag ELISA. Combination
indices (CI) were determined to evaluate the type of drug–drug
interactions, where CIb0.9 are synergistic, 0.9bCIb1.1 are additive
effects and CIN1.1 are antagonistic. The obtained CI values varied
between 0.44 and 0.53, resulting thus in synergy at the calculated EC95
level for each combination (Table 2).
Synergistic anti-HIV-1 activity of GRFT with tenofovir and maraviroc
against various clade C clinical isolates in PBMCs
The number of clade C HIV-1 infections dominates the number of
clade B infections in Africa. Consequently, an effectivemicrobicidemust
Table 3
Synergy calculations against various clade C HIV-1 clinical isolates after GRFT/tenofovir
and GRFT/maraviroc combination treatment.
HIV strains Synergya
Combi DJ259 ZAM18 ETH2220
GRFT/tenofovir ++(+) ++ ++
GRFT/maraviroc +++ +++ +++
a Synergy level: 0.85bCIb0.9: + (slight synergism); 0.7bCIb0.85: ++ (moderate
synergism); 0.3 bCI b0.7: +++ (synergism); 0.1 bCIb0.3: ++++ (potent
synergism).
Table 4
EC50 values of GRFT (nM), tenofovir (μM), enfuvirtide (nM) and AMD3100 (nM) alone
and in combination at equipotent (1:1) ratio against HIV-1 NL4.3 in MT-4 cells.
EC50 individual druga EC50 combinationb
GRFT Inhibitor GRFT Inhibitor
Tenofovir 0.10±0.02 6.3±0.6 0.029±0.006⁎ 1.9±0.5⁎
Enfuvirtide 0.12±0.02 23.7±5.5 0.015±0.003⁎ 4.9±0.7⁎
AMD3100 0.13±0.02 16.0±1.7 0.044±0.004⁎ 5.8±1.3⁎
a EC50 concentrations for individual drug treatment against NL4.3 infection in MT-4
cells. Mean values±SEM from 4 independent experiments are shown.
b EC50 concentrations (mean±SEM) after two-drug combinations at equipotent
ratio (1:1) from 4 individual experiments are shown.
⁎ pb0.05 (according to unpaired T-Test).
Table 2
Combination index determination for various GRFT combinations against clade B BaL in
PBMCs.
HIV-1 strain BaL (clade B)
Combination CIa Synergyb
GRFT/tenofovir 0.47±0.05 +++
GRFT/maraviroc 0.44±0.05 +++
GRFT/enfuvirtide 0.53±0.05 +++
a Combination index (CI) calculated at the EC95-level. CIb0.9 indicates synergism;
0.9bCIb1.1 indicates additive effects and CIN1.1 indicates antagonism. Mean CI±SEM
are shown.
b Synergy level: 0.85bCIb0.9: + (slight synergism); 0.7bCIb0.85: ++ (moderate
synergism); 0.3 bCI b0.7: +++ (synergism); 0.1 bCIb0.3: ++++ (potent
synergism).
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tions of GRFT with tenofovir and maraviroc against three clinical HIV-1
isolateswith different glycosylation patterns. The susceptibility of GRFT,
tenofovir and maraviroc, alone and their combinations against these
clade C viruses is shown in Table 1. Signiﬁcant reductionswere observed
for the GRFT 50% inhibitory dose in each combination with tenofovir
(pb0.05) (Table 1). With maraviroc, the EC50 for GRFT decreased
signiﬁcantly against ETH2220 (p=0.0405). It is important to note that
no large differenceswere observed in anti-HIV activity in PBMCs against
clade C viruses compared with clade B (Table 1). Overall, we can
conclude that combination of GRFT with tenofovir or maraviroc
increases its antiviral potency (Table 1). CI calculations showed synergy
between GRFT and tenofovir against the 3 isolates tested: DJ259 (CI,
0.70±0.10), ZAM18 (CI, 0.76±0.10) and ETH2220 (CI, 0.79±0.02)
(Table 3 and Fig. 2). A comparable synergistic interactionwas also found
after combination with maraviroc against DJ259 (CI, 0.67±0.08).Fig. 2. Mean combination indices (±SEM of 3–4 different PBMC donors) of GRFT/
tenofovir and GRFT/maraviroc determined against clade C R5 HIV-1 isolates DJ259,
ZAM18 and ETH2220.Stronger synergy was observed against ZAM18 and ETH2220 with CI
values of 0.51±0.14 and 0.59±0.24, respectively (Table 3 and Fig. 2).
GRFT is synergistic with tenofovir, enfuvirtide and AMD3100 against X4
NL4.3 in MT-4 cells
We further evaluated if synergistic interactions occur when GRFT
was combined with tenofovir, enfuvirtide and the speciﬁc CXCR4
antagonist AMD3100 onMT-4 cells using the laboratory-adapted HIV-1
X4 strain NL4.3. The EC50 values for each drug alone and in
combination are shown in Table 4. After combination, GRFT effective
concentrations decreased signiﬁcantly in each combination tested
(pb0.05) and a similar observation was noted for each combined
inhibitor (pb0.05; Table 4). As seen with the R5 HIV-1 strains, all
combinations increase the antiviral potency of GRFT against the X4
virus. The strongest synergistic interaction was observed between
GRFT and enfuvirtide (CI, 0.34±0.10; Table 5). A comparable
synergistic proﬁle was observed with the combinations GRFT/
tenofovir and GRFT/AMD3100 with a CI of 0.60±0.03 and 0.64±
0.06, respectively (Table 5).
Discussion
The proof-of-concept trial of a 1% tenofovir vaginal gel product
(CAPRISA 004) for the prevention of HIV infection in women opened
novel perspectives in the ﬁeld of microbicidal research (Abdool Karim
et al., 2010). However, like systemic treatment of HIV/AIDS infections,
single drug microbicides are perhaps not potent enough and could
also increase the risk of transmission of resistant viruses, making
combinations of at least 2 different antiretroviral drugs with broad-
spectrum anti-HIV activity the best prevention strategy against viral
transmission Klasse et al. (2008). An effective microbicide must also
have a good cervicovaginal safety and pharmacokinetic/dynamic
proﬁle (Doncel and Clark, 2010). Grifﬁthsin is not mitogenic and
showed no toxicity in rabbit vaginal irritation tests as well as no
induction of pro-inﬂammatory cytokines in human cervical explantsTable 5
Combination indices at the EC95 level of GRFT combinations in two-drug assays against
X4 HIV-1 NL4.3.
GRFT in combination with
Tenofovir AMD3100 Enfuvirtide
Combination indexa 0.60±0.03 0.64±0.06 0.34±0.10
Synergyb +++ +++ +++
a Combination index (CI) calculated at the EC95 level represented by themean value±
SEM from 4 independent experiments in MT-4 cells infected with HIV-1 NL4.3. CIb0.9
indicates synergism; 0.9bCIb1.1 indicates additive effects and CIN1.1 indicates
antagonism.
b Synergy level: 0.85bCIb0.9: + (slight synergism); 0.7bCIb0.85: ++ (moderate
synergism); 0.3 bCIb0.7: +++ (synergism); 0.1 bCI b0.3: ++++ (potent
synergism).
256 G. Férir et al. / Virology 417 (2011) 253–258at 2 μM (O'Keefe et al., 2009). We also found no induction of any
cytokines nor cellular activation markers in human PBMCs at 2 μM
using the Bio-plex Human Cytokine 27-plex assay (unpublished data).
GRFT belongs to the class of carbohydrate-binding agents (CBAs)
and is, to our knowledge, the most potent CBA described for
inhibiting HIV infection and replication in the pM range (Alexandre
et al., 2010; Mori et al., 2005; O'Keefe et al., 2009). CBAs are
attractive microbicide candidates as they target HIV at 4 different
intervention steps, namely (i) inhibition of cell-free virus replication
and (ii) inhibition of syncytium formation between uninfected
CD4+ T cells and HIV-infected T cells, (iii) inhibition of capture by
DC-SIGN and (iv) transmission of captured virus to uninfected CD4+ T
cells (Balzarini, 2007).
Certain sexually transmitted diseases (such as Chlamydia orHerpes
Simplex Virus) can increase the risk onHIV transmission (Abu-Raddad
et al., 2008; Baeten et al., 2007). The results of the CAPRISA 004 trial
showed that tenofovir also reduced the genital herpes infections
(Abdool Karim et al., 2010). In addition to its activity against HIV-1,
GRFT is also active against HSV-2 (Palmer et al., manuscript in
preparation). Given the established efﬁcacy of tenofovir vaginal gel
against HSV-2 acquisition, a GRFT/tenofovir combination microbicide
becomes an appealing product to combat HIV transmission.
Here, we showed that the potent anti-HIV CBA GRFT can be
combined with the nucleotide reverse transcriptase inhibitor (RTI),
tenofovir, the CCR5 HIV co-receptor antagonist, maraviroc and the
gp41 fusion inhibitor enfuvirtide and that all combinations are
synergistic against clade B (mainly present in the Americas,
Australasia and Europe) and clade C, which accounts for approxi-
mately 60% of the HIV-1 infections, worldwide (mainly in Africa and
the Indian subcontinent, with expanding epidemics elsewhere). By
combining GRFT with an entry inhibitor targeting ensuing steps in the
entry process or with a RTI, a broader range of (multi-drug resistant)
HIV subtypes can be blocked.
GRFT acts as a virucide by targeting multiple glycans present on
gp120 (Mori et al., 2005). Alexandre et al. (2010) showed that the N-
glycosylations on position 295 (N295) and 234 (N234) are crucial
binding sites for GRFT and their absence decreased its antiviral
potency. The HIV-1 strains NL4.3 (clade B) and DJ259 (clade C) both
contain these N-linked glycosylations. BaL (clade B) lacks N234,
ZAM18 (clade C) lacks N295 and ETH2220 (clade C) lacks both N-
glycosylations. The complete amino acid sequences are available in
GenBank with GenBank ID: AAB60578, BAH97458, ABC55874,
BAH97494 and Q75008 resp. (www.ncbi.nlm.nih.gov/protein). In
our experiments performed in PBMCs, GRFT lost almost no activity
against the three different clade C isolates compared to the well-
described and widely used laboratory strain clade B BaL (Table 1).
A strong hallmark of the class of CBAs is their high genetic barrier
to resistance and excellent physicochemical properties (e.g. resistant
to high temperature and low pH) (Balzarini et al., 2004; Huskens et al.,
2010). Grifﬁthsinmaintained its potent antiviral activity in both acidic
and alkaline pH (Emau et al., 2007) and we recently showed that
tenofovir can be combined with various other CBAs in vitro against R5
and X4 HIV-1 (Férir et al., 2011). In vivo studies using a tenofovir/GRFT
gel combination are planned to evaluate various antiviral efﬁcacy
parameters in preparation for human clinical studies.
Maraviroc is a speciﬁc CCR5 interacting small chemical molecule
with potent activity against R5 viruses (Dorr et al., 2005). For systemic
HIV treatment, maraviroc is used in combination with other
antiretroviral drugs and various studies have shown that it also has
potential for microbicidal applications. An open-labeled pharmacoki-
netical study in healthy women showed that orally administered
maraviroc concentrates in the female genital tract (Dumond et al.,
2009). A recent study using maraviroc in a gel-based formulation
protects rhesus macaques from infection with CCR5-tropic SHIV
(Veazey et al., 2010). GRFT shows synergistic interactions with
maraviroc against clade B and clade C HIV-1 strains (Tables 2 and 3),making a GRFT/maraviroc containing gel or controlled-release
intravaginal ring device good candidates for HIV prevention studies.
Although sexual transmission of HIV mainly occurs by R5 viruses,
presumably because of lower replication “ﬁtness” of X4 viruses, we
investigated potential synergistic interactions against X4 viruses. A
study with macaques showed that X4 viruses can also be transmitted
vaginally (Miller and Hu, 1999). We used CD4+ MT-4 cells, which are
CCR5− and CXCR4+, therefore in these experiments maraviroc was
replaced by the speciﬁc CXCR4 antagonist AMD3100 (Schols et al.,
1997). GRFT showed synergistic interactions in all combinations
tested against X4 HIV-1 NL4.3 (Table 5). Potent synergistic in-
teractions between enfuvirtide/AMD3100 in PBMCs were also
observed by other research groups (Tremblay et al., 2000).
Enfuvirtide showed potent anti-HIV activity, a safe pharmacoki-
netic proﬁle and became the ﬁrst approved peptidic entry inhibitor for
the treatment of HIV/AIDS infections (Kilby et al., 1998, 2002).
Enfuvirtide is mainly used in non-African countries, so we only
evaluated the combination with GRFT against HIV-1 BaL. Here we also
demonstrated that GRFT has synergistic interactions with enfuvirtide
against HIV-1 clade B. Since its discovery, novel derivatives of
enfuvirtide have been generated (such as T-1249 and T-2635). An
advantage of these fusion inhibitors compared with co-receptor
antagonists is their tropism independent antiviral activity. Macaques
that received a T-1249-containing vaginal gel showed inhibition of
SHIV replication (Veazey et al., 2008) and this peptide showed a
superior antiviral proﬁle compared with enfuvirtide. Resistance
analysis of this second generation peptide revealed that mutations
occur at position 38 (V38) in gp41 and resulted in enfuvirtide cross-
resistance. However, a third generation peptide, T-2635, retained its
antiviral activity (Eggink et al., 2008). These data and our observations
show that enfuvirtide (and its later generation peptides) could also be
useful in the prevention of HIV transmission.
Overall, due to its potent and broad-spectrum anti-HIV activity as
well as its synergistic interactions with tenofovir, maraviroc and
enfuvirtide, we believe that GRFT has a great potential as microbicide
in the prevention of sexual transmission of HIV when co-formulated
in appropriate gel or solid dosage form, or in a sustained-release
intravaginal ring device. All GRFT-antiretroviral combinations tested
showed a synergistic proﬁle, with improved antiviral potency. The
observed synergy for the GRFT/enfuvirtide and the GRFT/maraviroc
combinations may be a reﬂection of their common target, viral entry,
but the agents are targeting subsequent steps during the entry
process. As we showed previously with several other members of the
CBA family (e.g. microvirin and Hippeastrum Hybrid agglutinin), also
GRFT has no negative effects on the cellular uptake and processing of
the RTI tenofovir. Synergy may enable reductions in effective dose of
each component, with corresponding decreases in side-effect proﬁles,
and even reduction in the product costs. Our data strongly support
further translation research on these GRFT-antiretroviral combina-
tions as potential microbicides.
Materials and methods
Cells and cell culture
MT-4 cells were a gift from Dr. L. Montagnier (at that time at the
pasteur institute, Paris, France) and cultured in RPMI-1640 medium
containing 10% FCS (Hyclone, Perbio Science, Aalst, Belgium) and
2 mM L-glutamine (Invitrogen, Merelbeke, Belgium) at 37 °C and 5%
CO2. Peripheral blood mononuclear cells (PBMCs) from healthy
donors were isolated out of a buffy coat obtained from the Blood
Transfusion Center (U.Z. Leuven, Belgium). PBMCs were also cultured
RPMI-1640 supplemented with 10% FCS, 2 mM L-glutamine and
2 ng/ml IL-2 (Roche Molecular Biochemicals, Indianapolis, USA) and
activated with 2 μg/ml PHA (Sigma-Aldrich, Bornem, Belgium) for
3 days before antiviral testing.
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HIV-1 CCR5-tropic (R5) laboratory strain BaL (clade B) and HIV-1
CXCR4-tropic (X4) NL4.3 (clade B) were obtained through the AIDS
Research and Reference Reagent Program (Division of AIDS, NIAID,
NIH). The R5 primary clinical HIV-1 isolates DJ259, ZAM18 and
ETH2220 (all clade C) were kindly provided by Dr. J.L. Lathey (BBI
Biotech Research Laboratories, Inc., Gaithersburg, MD).
Compounds
GRFT was isolated and puriﬁed as described elsewhere (O'Keefe
et al., 2009). Enfuvirtide was a gift from Prof. Dr. E. Van Wijngaerden
(U.Z. Leuven, Belgium). AMD3100 and maraviroc were provided by
Dr. G Bridger (at that time by AnorMED Inc., Langley, British Columbia,
Canada). Tenofovir was obtained from Dr. A. Holý (Prague, Czech
Republic).
Antiviral assays and combination experiments
Methodology of antiretroviral assays for single drug testing and their
combinations at various ratios were in detail described earlier
(Vermeire et al., 2004). Brieﬂy, 3-fold dilutions of test compounds
were added in a 96-well plate and then MT-4 cells (5×104cells/well)
were seeded in the plate. After 20 min of pre-incubation, cells were
infected with 1000 pg/ml of p24 HIV-1 Ag of HIV-1 NL4.3. Cytopathic
effects (CPE) were scoredmicroscopically at day 5 and antiviral activity
wasmeasured byMTS/PESmethod as described (Vermeire et al., 2004).
PHA-activated PBMCs were resuspended in cell culture medium
containing 2 ng/ml IL-2 and then seeded in 48-well plates
(5×105cells/well) containing already cell culture medium with 3-
fold drug dilutions. After 20 min of pre-incubation, 500 pg/ml of HIV-1
p24 HIV-1 Ag (BaL, DJ259, ZAM18 or ETH2220) was added. IL-2 was
added after 3 and 6 days post-infection. At day 10, supernatant was
collected and viral replication was measured by p24 HIV-1 Ag ELISA
(Perkin Elmer, Zaventem, Belgium).
Combination indices (CI) were calculated using CalcuSyn software
(Biosoft, Cambridge, UK) based on the median effect principle of Chou
and Talalay (1984). CI-valueb0.9 indicates synergism, 0.9bCIb1.1
indicates additive effects and CIN1.1 indicates antagonism.
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